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Abstract Recently, genome-wide association studies
have identiWed loci across a segment of chromosome 8q24
(128,100,000–128,700,000) associated with the risk of
breast, colon and prostate cancers. At least three regions of
8q24 have been independently associated with prostate can-
cer risk; the most centromeric of which appears to be popu-
lation speciWc. Haplotypes in two contiguous but
independent loci, marked by rs6983267 and rs1447295,
have been identiWed in the Cancer Genetic Markers of Sus-
ceptibility project (http://cgems.cancer.gov), which geno-
typed more than 5,000 prostate cancer cases and 5,000
controls of European origin. The rs6983267 locus is also
strongly associated with colorectal cancer. To ascertain a
comprehensive catalog of common single-nucleotide poly-
morphisms (SNPs) across the two regions, we conducted a
resequence analysis of 136 kb (chr8: 128,473,000–
128,609,802) using the Roche/454 next-generation
sequencing technology in 39 prostate cancer cases and 40
controls of European origin. We have characterized a com-
prehensive catalog of common (MAF > 1%) SNPs within
this region, including 442 novel SNPs and have determined
the pattern of linkage disequilibrium across the region. Our
study has generated a detailed map of genetic variation
across the region, which should be useful for choosing
SNPs for Wne mapping of association signals in 8q24 and
investigations of the functional consequences of select
common variants.
Introduction
Recent genome-wide association (GWAS) and linkage
studies have identiWed common genetic variation in at least
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three independent regions of human chromosome 8q24
(128,100,000–128,700,000) that are associated with risk of
prostate cancer (Amundadottir et al. 2006; Freedman et al.
2006; Gudmundsson et al. 2007; Haiman et al. 2007b; Yea-
ger et al. 2007). The Wrst single-nucleotide polymorphism
(SNP) marker associated with prostate cancer risk was
rs1447295 (Amundadottir et al. 2006; Freedman et al.
2006), and in follow-up GWAS, two studies have reported
stronger signals of association in prostate cancer for two
markers, rs4242382 (Thomas et al. 2008) and rs4242384
(Eeles et al. 2008), both in strong linkage disequilibrium
(LD) with rs1447295. A second independent marker,
rs6983267, was identiWed by GWAS with replication;
though the two markers lie in contiguous blocks of LD,
they are separated by a recombination hotspot (Yeager
et al. 2007). Therefore, the two loci confer independent risk
for prostate cancer. A separate study focusing on non-Euro-
pean populations reported that two SNPs (rs10808556 and
rs7013278) in LD with rs6983267 are strongly linked with
rs6983267 and could capture signiWcant additional risk
(Haiman et al. 2007a). Furthermore, rs6983267 has also
been identiWed as a marker for colorectal cancer risk in four
independent GWAS (Gruber et al. 2007; Haiman et al.
2007a; Tomlinson et al. 2007; Zanke et al. 2007), and in
premalignant colorectal adenoma (Berndt et al. 2008).
Lastly, a fourth region has been established in breast can-
cer, marked by rs13281615, which is »58 kb centromeric
to rs6983267 and resides in a distinct block of LD (Easton
et al. 2007).
8q24 is commonly ampliWed in many diVerent types of
cancer, particularly in prostate and colorectal cancer (Cher
et al.  1996; Nupponen et al. 1998). Interestingly, in the
region of the association signals for breast, colorectal and
prostate cancer (128,100,000–128,700,000), there are no
known genes with the exception of a processed psuedogene
(POU5F1P1). Approximately 300 kb distal to this region is
the c-MYC oncogene (MYC) but in multiple large genome-
wide scans, so far there is no evidence for LD between
genetic variants in the MYC gene and the loci associated
with speciWc cancers.
To identify common alleles with low to moderate eVects,
GWAS have relied upon replication in independent data
sets to conWrm true associations (Chanock et al. 2007).
Because these studies are designed to discover new geno-
mic regions associated with human disease or traits using
SNPs as markers, it is unlikely that the conWrmed SNPs are
the actual disease-contributory genetic variants. It has also
been proposed that there may be signiWcant allelic hetero-
geneity within regions such as 8q24 and that there may be
more than one causal variant present that could regulate a
gene or pathway (Camp et al. 2007). Before conducting
additional genotyping in large data sets to pinpoint the best
markers for further functional study, an important step in
following up regions of association identiWed by GWAS is
the characterization of a comprehensive set of common and
uncommon genetic polymorphisms within each region. In
this regard, the determination that all genetic variation
strongly correlated (“tagged”) with the most highly disease-
associated SNP markers can focus attention on a subset of
variants for laboratory analysis of phenotypic diVerences.
Recent advances in next-generation sequencing tech-
nology promise to accelerate the determination of com-
prehensive surveys of variation in target regions, because
it is possible to resequence regions in multiple individuals
(ShaVer  2007). To facilitate the cataloging of common
genetic variation in this region of chromosome 8q24,
Roche/454 next-generation sequencing technology was
utilized to rapidly resequence a »136 kb region (chr8:
128,473,000–128,609,802) in 39 advanced prostate can-
cer cases and 40 controls from the Prostate, Lung, Colo-
rectal, and Ovarian Screening Trial (Hayes et al. 2005);
these subjects were drawn from cases and controls geno-
typed in the PLCO GWAS reported in the CGEMS pro-
ject (http://cgems.cancer.gov) (Yeager et al. 2007). The
sample size for analysis was deliberately chosen (158
chromosomes) to identify common SNPs, namely those
with a minor allele frequency (MAF) of greater than 1%
with a probability of 99% (Kruglyak and Nickerson
2001). Six HapMap CEU samples were also included for
quality-control assessment. Furthermore, the sampling
strategy using the Roche/454 technology could be com-
pared with the results generated by the Illumina technology
in the initial GWAS.
Materials and methods
Samples
Forty advanced prostate cancer cases and forty controls
from the National Cancer Institute’s Prostate, Lung, Colo-
rectal, and Ovarian Screening Trial (PLCO) were selected
from those DNA samples that were genotyped as part of the
Cancer Genetic Markers of Susceptibility (CGEMS)
GWAS (http://cgems.cancer.gov). PLCO samples and the
subset chosen for the initial GWAS have been described
previously (Gohagan et al. 2000; Yeager et al. 2007). One
case sample was later determined to be of poor quality and
the results were eliminated from the analysis.
Region selection
The region (chr8: 128,473,000–128,609,802) was chosen
based on the observed patterns of LD surrounding
rs6983267 and rs1447295 in the HapMap CEU samples
(n = 60 individuals) such that the disease-linked causativeHum Genet (2008) 124:161–170 163
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variant(s) is expected to be captured by this analysis; the
region was chosen such that the likelihood that the disease-
linked variant(s) would not fall within the chosen region is
very small (Yeager et al. 2007).
Primer design and PCR optimization process
PCR primers were designed to generate tiled amplicons
ranging in size between 2 and 5.5 kb overlapping across
150–600 bp segments. Primers were designed using NetPri-
mer (http://www.premierbiosoft.com/netprimer/netprlaunch/
netprlaunch.html). Primers were synthesized and HPLC-
puriWed (Integrated DNA Technologies, Coralville, IA).
Primer testing was performed using 125 ng of a commercial
pool of human genomic DNA (Roche Applied Science,
Indianapolis, IN) in a PCR core mix containing 200 nM of
each forward and reverse primers, 1X AccuPrime™ BuVer
II (Invitrogen, Carlsbad, CA) and two units of Accu-
Prime™ Taq DNA Polymerase High Fidelity (Invitrogen).
PCR primers and amplicon lengths are listed in Supplemen-
tary Table 1.
Thermal cycling was performed on a DNA Engine Tet-
rad® (Bio-Rad Laboratories, Hercules, CA) using the fol-
lowing “touch down” cycling proWle: one cycle at 95°C for
5 min (initial denaturation), followed by six cycles at 95°C
for 30 s (denaturation), at 65°C for 30 s (annealing; ¡1°C
every cycle) at 68°C for 3 min (extension), followed by 24
cycles at 95°C for 30 s (denaturation), at 60°C for 30 s
(annealing), at 68°C for 3 min (extension), followed by a
Wnal extension step at 68°C for 10 min. Upon visualization
of PCR products on 1% agarose gel, amplicons that failed
to amplify were attempted with up to three additional modi-
Wed thermal cycling conditions. The Wrst proWle stretched
all extension times to 6 min. The second proWle maintained
the 6-min extension and reduced the annealing temperature
for the last 24 cycles to 55°C. The third proWle maintained
the 6-min extension and dropped the annealing temperature
of the last 24 cycles to 50°C. The thermal cycling proWle
producing the strongest and cleanest amplicon was
recorded for each primer set. Any primer pair that failed to
amplify with all four PCR proWles was discarded and new
primers were designed. In such cases, new primers were
designed to maintain a minimum overlap of 150 bp with the
upstream amplicon and a minimum amplicon length of
2 kb.
Once all amplicons covering the target region were suc-
cessfully ampliWed, PCR products were cleaned up using an
equal volume of AMPure Reagent beads (Agencourt, Bev-
erly, MA) following the manufacturer’s protocol. Ampli-
cons were subsequently quantiWed using the Quant-iT™
PicoGreen® dsDNA reagent (Invitrogen). Amplicons were
then pooled at an equimolar ratio. Three micrograms to Wve
micrograms of DNA was used to make a sequencing
library.
Sequencing
Library preparation and sequencing was performed on a
Genome Sequencer FLX System (Roche Applied Science)
as previously described (Gilbert et al. 2007).
Data analysis
The sequence reads that passed QC were aligned to the ref-
erence sequence from the target region (chr8: 128,473,000–
128,609,802) using a BLAST-based approach. The total
numbers of the aligned reads for each position and the pro-
portion of each type of nucleotides were used for calling
genotypes for each position using a heuristic approach.
BrieXy, genotype calls per position were established when
total number of aligned reads exceeded a preset threshold
(n = 20). For each nucleotide position, genotypes were
called based on the proportion of each type of nucleotides.
For each sample, homozygote genotype was assigned if the
proportion of the nonreference allele was <15% or >85%.
Heterozygote genotype was assigned if the proportion is
between 30 and 70%. The samples with nonreference allele
proportions outside the above ranges were not assigned any
genotypes. Insertions and deletions were detected during
the alignment, but genotype calls were not made on this
class of polymorphisms.
Descriptive statistics
Completion, concordance, MAF estimations, deviations
from Wtness for Hardy–Weinberg proportion, pair-wise LD,
and tag SNP selection were computed using the GLU soft-
ware package (http://cgfweb.nci.nih.gov/development/
tooldev.html).
Enhancer and conservation prediction
SNPs that exhibited the highest correlations (r2 >0 . 9 )  w i t h
the most signiWcant single SNPs in the centromeric and
telomeric regions (rs6983267 and rs4242382, respectively)
(Thomas et al. 2008) were searched using publicly avail-
able bioinformatic tools, particularly searching for highly
conserved and/or predicted enhancer regions using the
UCSC Genome Browser (http://genome.ucsc.edu/) and
Vista Enhancer database (http://enhancer.lbl.gov/). Pre-
dicted enhancer elements are highly signiWcantly conserved
between humans, mice, and rats. Note that the predicted
enhancer that overlaps rs6983267 is conserved in chicken
in addition to humans, mice, and rats.164 Hum Genet (2008) 124:161–170
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Results
Coverage and depth
Figure 1 shows coverage distribution within the target
region. The average coverage depth within the target region
is at least Wftyfold (50£), with Xuctuations across the
region of interest (chr8: 128,473,000–128,609,802). There
were three regions that had no coverage for any samples
attempted (128,487,643–128,489,703, 128,602,123–
128,603,268, 128,609,417–128,609,802, 3,590 bp) and one
region of low coverage, less than 20£ (128,579,374–
128,584,587; cumulatively 5,213 bp).
SNP discovery
Genotype calls were successfully made for 1,004 possible
segregating sites. Of these, 562 sites had previously been
reported in the dbSNP database (http://www.ncbi.
nlm.nih.gov/projects/SNP), but 213 of the 562 were
monomorphic in our study sample set. Four hundred and
forty-two novel SNPs were discovered and had not, to our
knowledge, been described previously; 174 of these novel
SNPs were singletons in our sample set. The mean,
median, maximum, and minimum MAF estimates for 791
newly discovered and previously reported SNPs are
shown in Table 1, and the distribution of MAFs is shown
in Fig. 2; all MAF estimates for the study samples are
reported in Supplementary Table 2. Overall, 454 SNPs
were observed to occur at a frequency ¸5% across this
136 kb region. It should be noted, however, that because
of the relaxation of per-locus completion (as described
below), some of these estimates could vary. The position
of each SNP with an estimated MAF is depicted per posi-
tion in Fig. 3. For the SNPs detected in this resequence
analysis, the mean, median, maximum, and minimum dis-
tances between polymorphic sites were 165, 98, 1,414,
and 1 bp, respectively. Chromosomal positions, alleles,
MAFs, Xanking sequences, completion rates, and concor-
Fig. 1 Coverage distribution within the target region (chr8:
128,473,000–128,609,802). The depth of coverage is calculated based
on number of reads that mapped to that position. The X-axis is the rel-
ative position from the start of the target region. The colored horizontal
bars at lower portion of the plot indicate the position of the amplicons
from long range PCR (Supplementary Table 1)
Table 1 Summary of minor allele frequency information for newly-
described (“non-dbSNP”) and dbSNP single-nucleotide polymor-
phisms
Non-dbSNP dbSNP
Number of monomorphic SNPs n/a 213
Number of polymorphic SNPs 442 349
Minimum MAF 0.006 0.000
Maximum MAF  0.464 0.500
Mean MAF 0.060 0.142
Median MAF 0.013 0.101
Fig. 2 Distribution of minor allele frequencies for newly discovered
and previously reported SNPs
Fig. 3 Minor allele frequency estimations for 442 polymorphic novel
SNPs and 562 SNPs that had previously been reported in dbSNP across
the 8q24 regionHum Genet (2008) 124:161–170 165
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dance rates for all SNPs are included in Supplementary
Table 2.
Completion rates
For each SNP and sample, percent genotyping completion
rates were calculated. One of the 80 study samples, a pros-
tate cancer case, consistently exhibited an extremely low
completion rate and, therefore, was dropped from subse-
quent analyses. After removal, the global completion rate
for all remaining samples and polymorphic loci was 93.5%
(range 77.1–99.2% for samples and 7.7–100% for loci).
Because this study was primarily focused on SNP discov-
ery, no loci were dropped due to low completion rates.
Completion rates per locus are included in Fig. 4 and
detailed in Supplementary Table 2.
Concordance with GWAS
Because 79 DNA study samples in this project were also
previously genotyped as a part of the initial CGEMS
GWAS, concordance with the genotype data generated
using the Illumina InWnium HumanHap550 array was
assessed for 39 SNPs across this interval. Overall concor-
dance per locus was 99.45%; genotype concordance for 28
SNPs was 100%, >98% for 10 SNPs, and >95% for the one
remaining SNP (rs17467139). For the study samples, the
overall concordance rate per sample was 99.45%, the
majority (71/79 retained in the analysis) of the samples dis-
played 100% concordance, six samples were >95% concor-
dant, though one sample was only 77% concordant
(described above and dropped from the analysis). These
high concordance values are particularly reassuring, since
the comparisons are of genotypes derived from multiple
technology platforms.
Fitness for Hardy–Weinberg proportions analysis
All polymorphic loci were tested for deviations from Wtness
for Hardy–Weinberg proportions. Only a small percentage
(»2%) of SNPs signiWcantly (P < 0.001) failed to meet
Wtness for Hardy–Weinberg proportion; the 17 SNPs that
failed were removed from subsequent analyses. Of the
“SNPs” that failed, nearly all were due to an extreme
excess of heterozygotes, which may be due to an early ver-
sion of the algorithm used to call SNP genotypes and are
therefore not reported.
Linkage disequilibrium
Pair-wise LD between all polymorphic sites was estimated
using TagZilla (http://tagzilla.nci.nih.gov). The patterns of
LD within this region have been reWned, particularly in the
region surrounding rs6983267, as shown in Fig. 5. The
marker that is most highly signiWcantly associated with
prostate cancer in the most centromeric portion of this
region, rs6983267 (Yeager et al. 2007; (Thomas et al.
2008), is highly correlated (r2 > 0.9) with one other SNP
(rs12682374, r2 = 0.942), while the most highly signiWcant
SNP in the telomeric portion of this region, rs4242382
(Thomas et al. 2008), was highly correlated with 43 SNPs
(r2 = 1.00: rs9297760, rs9297759, rs7824868, rs7814837,
rs7812894, rs7812429, rs7017300, rs7005132, rs4641026,
rs4582524, rs4515512, rs4498506, rs4314621, rs4297007,
rs4242384, rs6470518, rs6470519, rs6470520, rs1447295,
rs4871802, rs10109700, rs7826179, rs7832031, rs13255059,
rs10090154, rs4242385; r2 = 0.95: rs11988857, rs9656816,
rs9643226, rs1447296, rs12545648, rs10099413,
rs10088308, rs7818556, rs8180905, rs1447292, rs4431561,
rs7837688, rs4871801, rs4871024, rs3956790; r2 =0 . 9 1 :
rs4871798 and rs3999775). Because the polymorphisms
within these two groups are so highly correlated with these
two associated markers, it is probable that we have deter-
mined the SNP sites that will ultimately be established as
the actual causal variant(s) in each independent locus.
However, because of lower completion rates at select loci,
the presented results provide an exploratory analysis of a
dense set of SNPs. Pair-wise r2 and D values for all SNPs
with a MAF >5% between rs6983267 and rs4242382 are
included in Supplementary Table 3.
Tag SNP selection
Using the 79 unrelated individuals, we estimated tag SNPs
for the entire region (r2 ¸ 0.9, minimum MAF ¸ 0.05)
using the TagZilla software package (http://tagzilla.nci.
nih.gov). TagZilla computes tag SNPs based on a modiWca-
tion of an algorithm that has been proposed by Carlson
et al. (2004). From the present data, at an r2 ¸ 0.8, 114
SNPs are necessary to tag 100% of the 454 SNPs that were
observed at an estimated MAF ¸ 0.05 (Table 2). Publicly
available data is available for 174 SNPs within this region
in HapMapII. Using HapMap SNPs alone, 53 bins monitor-
ing 353 SNPs are covered, whereas 62 bins (monitoring
101 SNPs) are not monitored by any known HapMap SNP.
Fig. 4 Completion rates per lo-
cus and per sample166 Hum Genet (2008) 124:161–170
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Therefore, using HapMap SNPs alone, total coverage of
this region is approximately 78%. We observed that an
additional 125 SNPs reported in the dbSNP database that
were not genotyped as part of the HapMap project had esti-
mated MAFs ¸ 0.05 (Table 2). Genotyping these 125
SNPs + the additional 174 SNPs would provide 90% cover-
age for this region. However, it should be noted that since
complete genotype data are not available for these 125
SNPs, all of them would have to be genotyped (along with
the 53 HapMap tags) within a suitable sample to derive
detailed tagging information. An additional 34 tags moni-
toring 44 total SNPs described in this study were not other-
wise covered by any entry in dbSNP. All relevant bin
information for the 454 SNPs with an estimated
MAF ¸ 0.05 is included in Supplementary Table 4.
Enhancer and conservation prediction
Because the expectation is that a causal variant will be in
very strong LD with the SNP markers that have been geno-
typed and found to be associated with prostate cancer, to
begin to prioritize SNPs to be followed up with functional
and other nonbioinformatic studies, we explored the two
regions using the UCSC browser (http://genome.ucsc.edu/)
and VISTA Enhancer database (http://enhancer.lbl.gov/) to
determine whether the SNPs that are most highly correlated
with the top SNPs from the two regions may lie within
regions that are highly conserved across mammals and
other vertebrate species and/or lie within predicted
enhancer elements or other potential regulatory regions. As
stated above, for the centromeric and telomeric regions, 2
and 44 SNPs that meet these criteria were nominated,
respectively.
For the centromeric region, rs6983267 proved to be the
best candidate, falling within a highly conserved (1,083 bp,
chr8: 128,481,736–128,482,819, Human Genome Build
36.2) segment that has strong regulatory potential and also
contains a putative enhancer chr8: 128,482,390–
128,483,622 (UCSC Genome Browser; http://genome.
ucsc.edu; May 2004 assembly) (Fig. 6). Under the assump-
tion of a single functional SNP in the LD block, the func-
tional SNP should have a high MAF; therefore, the
likelihood that another SNP exists that has been overlooked
within this study is extremely small. The enhancer activity
of this segment remains to be experimentally assessed. Two
other SNPs fall within or very near this segment,
Fig. 5 ReWnement of linkage 
disequilibrium among 
SNPs > 0.05 MAF across the 
8q24 region, with approximate 
positions of SNPs that have been 
implicated in prostate cancer 
risk: rs6983267, rs1447295, and 
rs4242382 are denoted by ar-
rows (from left to right, respec-
tively)
Table 2 Bin and SNP coverage by data source for chromosome 8: 128,473,000–128,609,802
a dbSNP includes all HapMap and an additional 125 non-HapMap SNPs within this region
b Previously unreported in dbSNP
Data source Number of bins 
monitored
Number of 
SNPs monitored
Number of bins 
not monitored
Number of SNPs 
not monitored
Coverage (%)
HapMap (n = 174) 53 353 62 101 78
dbSNP (n = 299)a 80 410 34 44 90
Novel (n =1 5 5 ) b 34 44 80 410 10
All SNPs (n = 454) 114 454 0 0 100Hum Genet (2008) 124:161–170 167
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rs10808556 and rs7008058. rs10808556 has an r2 of 0.692
with rs6983267, and rs7008058 is not polymorphic in this
sample.
The 44 SNPs in the telomeric region were similarly
examined, though none proved highly compelling using
this method. One SNP (rs4431561, r2 with
rs4242382 = 0.949) fell within a highly conserved region,
one SNP (rs1447296, r2 with rs4242382 = 0.952) was
located in a putative enhancer region, and one SNP
(rs7812894, r2 with rs4242382 = 1.0) was located in a pre-
dicted region of regulatory potential. All other SNPs did
not clearly fall within any of these three region types; and
although this does not exclude them from being candidates
for the causal variant(s), it makes them less likely.
Discussion
Genome-wide association studies with suYciently large
replication components are rapidly identifying regions of
the genome that are convincingly associated with risk of
cancer and other diseases (Manolio et al. 2008; Rahim et al.
2008). Because the majority of GWAS studies take an
approach that is unbiased with respect to function, the
genotyped SNPs associated with a disease or trait are not
necessarily the functional variants, rather, they are viewed
as markers correlated with the true causative variant(s). The
identiWcation of a marker association represents the begin-
ning of a process to deWne the causal variants through func-
tional analyses and molecular phenotyping.
Characterizing all genetic polymorphisms within a
region, as we have done here, is a critical next step to
GWAS. SNP markers discovered or further characterized
as a part of these require subsequent genotyping in suY-
ciently large sample sets to reWne association signals prior
to dedicated laboratory analysis. Two advantages of charac-
terizing all common genetic variants prior to undergoing
large-scale Wne-mapping studies are (1) that all common
genetic variants may be represented using a tag SNP
approach, and (2) the correlations among all genetic vari-
ants will be known, which will allow for rapid nomination
of variants for functional studies for those that are most
highly correlated with the markers that are most highly
associated with disease.
At least four regions of human chromosome 8q24 have
recently been implicated in the risk of prostate, breast, and
colorectal cancer (Amundadottir et al. 2006; Freedman
et al. 2006; Gruber et al. 2007; Gudmundsson et al. 2007;
Haiman et al. 2007a,  b; Schumacher et al. 2007; Yeager
et al.  2007; Zanke et al. 2007) and colorectal adenoma
Fig. 6 Best SNP from centro-
meric region (rs6983267), con-
servation, regulatory potential, 
and enhancer element probabili-
ties. Vista enhancer tracks are 
shown on the UCSC browser. 
The level of conservation is dis-
played on the vertical axis. 
Scores for regulatory potential 
compare frequencies of short 
alignment patterns between 
known regulatory elements and 
neutral DNA. They are com-
puted from human, chimp, 
macaque, mouse, rat, dog, and 
cow alignments (King et al. 
2005). The location of 
rs6983267 is indicated with a 
red line168 Hum Genet (2008) 124:161–170
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(Berndt et al. 2008). Replication of markers in 8q24 has
been robust, but candidate variants for functional analyses
remain elusive, especially in a region with a dearth of can-
didate genes. The recent emergence of next-generation
sequencing technologies provides an unprecedented avenue
to quickly and relatively inexpensively characterize genetic
variation in fairly large genomic regions for medium-sized
sample sets that are designed to detect with great proba-
bility common (>1%) variants. In this report, we have
utilized the 454/Roche next-generation sequencing technol-
ogy to characterize with great certainty and high quality all
common variation within two of these regions (chr8:
128,473,000–128,609,802), including what will most likely
be the variant(s) associated with prostate and colorectal
cancers. We have determined that this region of 8q24
contains 780 common SNPs, 454 of which have a
MAF ¸ 0.05.
Based on our sequence analysis of 158 chromosomes,
we have constructed a map of LD across the region. One
hundred and fourteen SNPs are necessary to comprehen-
sively tag this region for further association studies in indi-
viduals of European ancestry with an r2 > 0.8. Genotyping
53 of 174 HapMap tag SNPs alone would cover approxi-
mately 78% of SNPs in this region in populations of Euro-
pean ancestry; the addition of 125 non-HapMap SNPs
previously reported in dbSNP raises coverage to approxi-
mately 90%, though it is worth noting that all 299 SNPs
would have to be genotyped to ensure this coverage. The
present study not only validates these 299 SNPs, but also
provides an additional 10% of information that would have
not been monitored.
A PHASE analysis of common genetic variation
(MAF > 5%) indicates a complex haplotype structure in
which there is recent recombination that generates a large
number of rarer haplotypes. Therefore, to interrogate this
region eYciently in association studies, it appears that tag
SNPs represent a more eYcient approach, with respect to
the number of required SNPs. Moreover, choosing tagSNPs
with a high threshold for r2 can improve the opportunity to
monitor more SNPs and rare haplotypes, but at the cost of
an increase in the number of SNPs needed for follow-up
genotype analysis.
Preliminary bioinformatic analyses have identiWed
rs6983267 as an excellent SNP for functional assessment.
Indeed it lies within a region that is both highly conserved
across vertebrates predicted to likely contain regulatory poten-
tial and an enhancer-element (see Fig. 6). It has been proposed
that variation within evolutionary-conserved regions is likely
associated with phenotypic diVerences that may contribute to
human diseases (Dermitzakis et al. 2005). For the telomeric
rs1447295 region, three SNPs lie within potentially interest-
ing regions, though strong evidence for nominating one of
them as the strongest candidate is still lacking.
In summary, we have extensively characterized the
majority of all common SNPs across two high-interest
regions, totaling »136 kb of human chromosome 8q24 that
have been reported to be associated with colon and/or pros-
tate cancer as identiWed by GWAS, replication, and other
case–control studies. We have veriWed that 299 SNPs that
have been deposited in dbSNP are polymorphic in our
samples (158 chromosomes), and have identiWed 442 novel
polymorphisms, 101 of which have an estimated
MAF ¸ 0.05 and are not monitored by HapMap SNPs at an
r2 of 0.8 in our sample population. Our data set provides an
important resource that may be used to design Wne-mapping
projects for this region. Such eVorts are critical for providing
suYcient information for rapidly following up association
Wndings and for Wne mapping project for regions of the
genome that are found to be signiWcantly associated with a
disease or phenotype. Our results underscore the value of
resequence analysis in determining the full catalog of
variants necessary to choose for further genotyping and
functional analyses. Finally, the determination of the corre-
lations among all genetic variation within this region
should expedite the nomination of variants for functional
studies post-Wne-mapping.
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